Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction

Hong Ma, Li Wang, Jiandong Liu, Li Qian

Research output: Chapter in Book/Report/Conference proceedingChapter

  • 2 Citations

Abstract

Direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs) holds great promise as a novel therapy for the treatment of heart failure, a common and morbid disease that is usually caused by irreversible loss of functional cardiomyocytes (CMs). Recently, we and others showed that in a murine model of acute myocardial infarction, delivery of three transcription factors, Gata4, Mef2c, and Tbx5 converted endogenous cardiac fibroblasts into functional iCMs. These iCMs integrated electrically and mechanically with surrounding myocardium, resulting in a reduction in scar size and an improvement in heart function. Our findings suggest that iCM reprogramming may be a means of regenerating functional CMs in vivo for patients with heart disease. However, because relatively little is known about the factors that regulate iCM reprogramming, the applicability of iCM reprogramming is currently limited to the experimental settings in which it has been attempted. Specific hurdles include the relatively low conversion rate of iCMs and the need for reprogramming to occur in the context of acute injury. Therefore, before this treatment can become a viable therapy for human heart disease, the optimal condition for efficient iCM generation must be determined. Here, we provide a detailed protocol for both in vitro and in vivo iCM generation that has been optimized so far in our lab. We hope that this protocol will lay a foundation for future further improvement of iCM generation and provide a platform for mechanistic studies.

LanguageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages69-88
Number of pages20
DOIs
StatePublished - Jan 1 2017

Publication series

NameMethods in Molecular Biology
Volume1521
ISSN (Print)1064-3745

Fingerprint

Cardiac Myocytes
Myocardial Infarction
Heart Diseases
Therapeutics
Fibroblasts
Treatment Failure
Cicatrix
Myocardium
Transcription Factors
Heart Failure
Wounds and Injuries

Keywords

  • Cell reprogramming
  • Fibroblast
  • Induced cardiomyocyte
  • Myocardial infarction
  • Regeneration

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Ma, H., Wang, L., Liu, J., & Qian, L. (2017). Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction. In Methods in Molecular Biology (pp. 69-88). (Methods in Molecular Biology; Vol. 1521). Humana Press Inc.. DOI: 10.1007/978-1-4939-6588-5_5

Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction. / Ma, Hong; Wang, Li; Liu, Jiandong; Qian, Li.

Methods in Molecular Biology. Humana Press Inc., 2017. p. 69-88 (Methods in Molecular Biology; Vol. 1521).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ma, H, Wang, L, Liu, J & Qian, L 2017, Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1521, Humana Press Inc., pp. 69-88. DOI: 10.1007/978-1-4939-6588-5_5
Ma H, Wang L, Liu J, Qian L. Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction. In Methods in Molecular Biology. Humana Press Inc.2017. p. 69-88. (Methods in Molecular Biology). Available from, DOI: 10.1007/978-1-4939-6588-5_5
Ma, Hong ; Wang, Li ; Liu, Jiandong ; Qian, Li. / Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction. Methods in Molecular Biology. Humana Press Inc., 2017. pp. 69-88 (Methods in Molecular Biology).
@inbook{c2c3cfba4311473d9b3cfc4f61927a89,
title = "Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction",
abstract = "Direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs) holds great promise as a novel therapy for the treatment of heart failure, a common and morbid disease that is usually caused by irreversible loss of functional cardiomyocytes (CMs). Recently, we and others showed that in a murine model of acute myocardial infarction, delivery of three transcription factors, Gata4, Mef2c, and Tbx5 converted endogenous cardiac fibroblasts into functional iCMs. These iCMs integrated electrically and mechanically with surrounding myocardium, resulting in a reduction in scar size and an improvement in heart function. Our findings suggest that iCM reprogramming may be a means of regenerating functional CMs in vivo for patients with heart disease. However, because relatively little is known about the factors that regulate iCM reprogramming, the applicability of iCM reprogramming is currently limited to the experimental settings in which it has been attempted. Specific hurdles include the relatively low conversion rate of iCMs and the need for reprogramming to occur in the context of acute injury. Therefore, before this treatment can become a viable therapy for human heart disease, the optimal condition for efficient iCM generation must be determined. Here, we provide a detailed protocol for both in vitro and in vivo iCM generation that has been optimized so far in our lab. We hope that this protocol will lay a foundation for future further improvement of iCM generation and provide a platform for mechanistic studies.",
keywords = "Cell reprogramming, Fibroblast, Induced cardiomyocyte, Myocardial infarction, Regeneration",
author = "Hong Ma and Li Wang and Jiandong Liu and Li Qian",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-6588-5_5",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "69--88",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Direct cardiac reprogramming as a novel therapeutic strategy for treatment of myocardial infarction

AU - Ma,Hong

AU - Wang,Li

AU - Liu,Jiandong

AU - Qian,Li

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs) holds great promise as a novel therapy for the treatment of heart failure, a common and morbid disease that is usually caused by irreversible loss of functional cardiomyocytes (CMs). Recently, we and others showed that in a murine model of acute myocardial infarction, delivery of three transcription factors, Gata4, Mef2c, and Tbx5 converted endogenous cardiac fibroblasts into functional iCMs. These iCMs integrated electrically and mechanically with surrounding myocardium, resulting in a reduction in scar size and an improvement in heart function. Our findings suggest that iCM reprogramming may be a means of regenerating functional CMs in vivo for patients with heart disease. However, because relatively little is known about the factors that regulate iCM reprogramming, the applicability of iCM reprogramming is currently limited to the experimental settings in which it has been attempted. Specific hurdles include the relatively low conversion rate of iCMs and the need for reprogramming to occur in the context of acute injury. Therefore, before this treatment can become a viable therapy for human heart disease, the optimal condition for efficient iCM generation must be determined. Here, we provide a detailed protocol for both in vitro and in vivo iCM generation that has been optimized so far in our lab. We hope that this protocol will lay a foundation for future further improvement of iCM generation and provide a platform for mechanistic studies.

AB - Direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs) holds great promise as a novel therapy for the treatment of heart failure, a common and morbid disease that is usually caused by irreversible loss of functional cardiomyocytes (CMs). Recently, we and others showed that in a murine model of acute myocardial infarction, delivery of three transcription factors, Gata4, Mef2c, and Tbx5 converted endogenous cardiac fibroblasts into functional iCMs. These iCMs integrated electrically and mechanically with surrounding myocardium, resulting in a reduction in scar size and an improvement in heart function. Our findings suggest that iCM reprogramming may be a means of regenerating functional CMs in vivo for patients with heart disease. However, because relatively little is known about the factors that regulate iCM reprogramming, the applicability of iCM reprogramming is currently limited to the experimental settings in which it has been attempted. Specific hurdles include the relatively low conversion rate of iCMs and the need for reprogramming to occur in the context of acute injury. Therefore, before this treatment can become a viable therapy for human heart disease, the optimal condition for efficient iCM generation must be determined. Here, we provide a detailed protocol for both in vitro and in vivo iCM generation that has been optimized so far in our lab. We hope that this protocol will lay a foundation for future further improvement of iCM generation and provide a platform for mechanistic studies.

KW - Cell reprogramming

KW - Fibroblast

KW - Induced cardiomyocyte

KW - Myocardial infarction

KW - Regeneration

UR - http://www.scopus.com/inward/record.url?scp=85005952430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005952430&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-6588-5_5

DO - 10.1007/978-1-4939-6588-5_5

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 69

EP - 88

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -